TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17519056

Group type: EXPERIMENTAL
Intervention: Telepsychiatry
Number of subjects: 38

Group type: COMPARATOR
Intervention: Same-room treatment
Number of subjects: 38
Study: 15189943

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) 24 micro g/kg/h, continuous IV infusion for 96 ± 1 h
Number of subjects: 273

Group type: COMPARATOR
Intervention: Drotrecogin alfa (activated)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo groups from PROWESS US trial
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo groups from sPLA2I trial
Number of subjects: 273

Group type: COMPARATOR
Intervention: Drotrecogin alfa (activated) in PROWESS US trial
Number of subjects: 273
Study: 11440912

Group type: EXPERIMENTAL
Intervention: High protein intake (1.5 g/kg/day) with [(15)N]alanine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low protein intake (0.3 g/kg/day) with [(15)N]alanine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High protein intake (1.5 g/kg/day) with [(15)N]Spirulina platensis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low protein intake (0.3 g/kg/day) with [(15)N]Spirulina platensis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Test meal with [(15)N]alanine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Test meal with [(15)N]Spirulina platensis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subjects with IDDM consuming test meal with [(15)N]alanine
Number of subjects: 12
Study: 10051934

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 100
Study: 7973475

Group type: EXPERIMENTAL
Intervention: MTX 7.5 mg/week and CHLO 250 mg/day
Number of subjects: 82

Group type: COMPARATOR
Intervention: MTX 7.5 mg/week and PLA 1 tablet/day
Number of subjects: 82
Study: 30342256

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention (depression prevention program)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Health education group (didactic control)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Health education group
Number of subjects: 150
Study: 27753600

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3199

Group type: COMPARATOR
Intervention: UFH plus GPI
Number of subjects: 3199
Study: 25440560

Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya and related practices (SK&P) for six weeks
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (sitting in an armchair with eyes closed and gentle attention to breath for six weeks)
Number of subjects: 230
Study: 22524487

Group type: EXPERIMENTAL
Intervention: GlideScope (GS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fastrach (FT)
Number of subjects: 100
Study: 20687940

Group type: EXPERIMENTAL
Intervention: 1 x 60 min specific strength training with training supervision
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: 3 x 20 min specific strength training with training supervision
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: 9 x 7 min specific strength training with training supervision
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: 3 x 20 min specific strength training with minimal supervision
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Reference group without training
Number of subjects: 2000
Study: 18716531

Group type: EXPERIMENTAL
Intervention: Wound infiltration with xylocaine
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Regular oral analgesics
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Routine oral analgesics
Number of subjects: 115
Study: 16643392

Group type: EXPERIMENTAL
Intervention: Septal pacing
Number of subjects: 28

Group type: COMPARATOR
Intervention: Apical pacing
Number of subjects: 28
Study: 12855302

Group type: EXPERIMENTAL
Intervention: Stride frequency (F) at 1 Hz
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Smaller stride length (L)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Freely chosen walking speeds
Number of subjects: 8
Study: 10985269

Group type: EXPERIMENTAL
Intervention: Formal process analysis and implementation of new practice guidelines
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Formal process analysis phase
Number of subjects: 37

Group type: COMPARATOR
Intervention: Before implementation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: After implementation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: During formal process analysis
Number of subjects: 37
Study: 8799540

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 1735859

Group type: EXPERIMENTAL
Intervention: Three radial incisions at 12, 4 and 8 o'clock
Number of subjects: 16

Group type: COMPARATOR
Intervention: Four radial incisions at 12, 3, 6, and 9 o'clock
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Three radial incisions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Four radial incisions
Number of subjects: 16
Study: 6385206

Group type: EXPERIMENTAL
Intervention: Efamol (1500 mg X 2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29676980

Group type: EXPERIMENTAL
Intervention: 10% HP gel (low viscosity)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10% HP gel (medium viscosity)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10% HP gel (high viscosity)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Crest 3D Whitestrips 1‐Hour Express
Number of subjects: 120

Group type: COMPARATOR
Intervention: medium viscosity gel without HP (negative control)
Number of subjects: 120
Study: 27479460

Group type: EXPERIMENTAL
Intervention: INCShort (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: INCLong (n=12)
Number of subjects: 24
Study: 25304787

Group type: EXPERIMENTAL
Intervention: Laser surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 60
Study: 21840136

Group type: EXPERIMENTAL
Intervention: Phenylbutyrate 5% mouthwash
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 36
Study: 20542081

Group type: EXPERIMENTAL
Intervention: Meaningful action preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meaningless action preparation
Number of subjects: 0
Study: 18493141

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 15888511

Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clonidine (300 microg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Temazepam (15 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12559511

Group type: EXPERIMENTAL
Intervention: Interferon beta 1a (IFNb1a)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon beta 1b (IFNb1b)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon beta 1a (IFNb1a) in SPECTRIMS trial
Number of subjects: 0
Study: 10463516

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) 500 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) 750 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination therapy with ddI/ZDV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination therapy with zalcitabine/ZDV
Number of subjects: 0
Study: 9035703

Group type: EXPERIMENTAL
Intervention: Tazarotene gel applied once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tazarotene gel
Number of subjects: 0
Study: 1751274

Group type: EXPERIMENTAL
Intervention: Dopamine 2.5 micrograms kg‐1 min‐1
Number of subjects: 142

Group type: COMPARATOR
Intervention: Dobutamine 2.5 micrograms kg‐1 min‐1
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Dopamine 2.5 micrograms kg‐1 min‐1 (in subgroup with CPB > 2h)
Number of subjects: 142
Study: 7201839

Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine (2 mg, three times a day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Piracetam (0.8 g, three times a day)
Number of subjects: 44
Study: 31389771

Group type: EXPERIMENTAL
Intervention: Stratified permuted-block randomization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple randomization
Number of subjects: 0
Study: 29433493

Group type: EXPERIMENTAL
Intervention: Integrated Individual Placement and Support (IPS) with pain treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 26651393

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine supplementation during pregnancy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 23322312

Group type: EXPERIMENTAL
Intervention: Philip Morris 'QuitAssist' PSA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Legacy 'truth' antismoking PSA
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control PSA
Number of subjects: 56
Study: 22257126

Group type: EXPERIMENTAL
Intervention: Fluoxetine (n=157)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo (n=152)
Number of subjects: 309
Study: 20376490

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional method (TM)
Number of subjects: 120
Study: 18179325

Group type: EXPERIMENTAL
Intervention: Imagining being in a meaningful location for the final time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reminded of the ending on graduation day
Number of subjects: 0
Study: 15721840

Group type: EXPERIMENTAL
Intervention: LPS (lipopolysaccharide)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 9
Study: 12872363

Group type: EXPERIMENTAL
Intervention: Iseganan
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 10859864

Group type: EXPERIMENTAL
Intervention: 0.1 ml PCECV intradermally at two sites on days 0, 3, 7, and at one site on days 30 and 90
Number of subjects: 211

Group type: COMPARATOR
Intervention: Purified Vero cell rabies vaccine (PVRV) administered similarly to Group 1
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: 1.0 ml PCECV intramuscularly on days 0, 3, 7, 14, 30 and 90
Number of subjects: 211
Study: 9174306

Group type: EXPERIMENTAL
Intervention: Multiport epidural catheters
Number of subjects: 500

Group type: COMPARATOR
Intervention: Uniport epidural catheters
Number of subjects: 500

Group type: COMPARATOR
Intervention: Multiport and Uniport epidural catheters
Number of subjects: 500
Study: 8517428

Group type: EXPERIMENTAL
Intervention: Low salt diet (20 mEq/day sodium)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low salt diet with enalapril
Number of subjects: 9

Group type: COMPARATOR
Intervention: High salt diet (20 mEq/day sodium + eleven 1 g salt tablets per day)
Number of subjects: 9
Study: 2872814

Group type: EXPERIMENTAL
Intervention: 1 mg terazosin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 mg terazosin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg terazosin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30685455

Group type: EXPERIMENTAL
Intervention: Continuous personal carbon monoxide (CO) exposure
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Second-hand tobacco smoke exposure
Number of subjects: 840
Study: 29713249

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA (capsules containing 180 mg of eicosapentaenoic acid and 120 mg of docosahexaenoic acid)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (gelatin capsules)
Number of subjects: 30
Study: 26959502

Group type: EXPERIMENTAL
Intervention: Mobile screening and teleophthalmology for diabetic retinopathy and maculopathy assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile screening and teleophthalmology for diabetic maculopathy assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile unit laser photocoagulation treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Referral to outpatient eye clinic for follow-up treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of visual acuity
Number of subjects: 0
Study: 24865696

Group type: EXPERIMENTAL
Intervention: 0.5 gI/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.4 gI/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.3 gI/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.28 gI/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 9.6 gI/m(2)
Number of subjects: 150
Study: 22710865

Group type: EXPERIMENTAL
Intervention: Neopterin levels before induction chemotherapy (day 0) in patient group 1 (children with acute leukemia)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Neopterin levels in control group 1 (children with infection)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Neopterin levels at day 15 of induction in patient group 1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Neopterin levels at day 33 of induction in patient group 1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Neopterin levels during neutropenic fever in patient group 2
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Neopterin levels in patients with microbiologically and/or clinically documented infections vs those with fever of unknown origin in patient group 2
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Correlation of serum neopterin with absolute neutrophil count and absolute monocyte count
Number of subjects: 44
Study: 20075952

Group type: EXPERIMENTAL
Intervention: Epoetin-alfa treatment to a target hemoglobin level of 13.5 g/dl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Target hemoglobin level of 11.3 g/dl
Number of subjects: 0
Study: 17392660

Group type: EXPERIMENTAL
Intervention: Alcohol septal ablation (ASA) - 1-3 ml of absolute alcohol introduced into the septal branch to create a controlled septal infarction.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical myectomy
Number of subjects: 0
Study: 15652878

Group type: EXPERIMENTAL
Intervention: Euthymic bipolar disorder patients (n=15)
Number of subjects: 15

Group type: COMPARATOR
Intervention: First-degree relatives of bipolar probands (n=27)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Remitted patients with major depressive disorder (n=15)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control subjects (n=15 for experiment 1, n=46 for experiment 2)
Number of subjects: 15
Study: 11966509

Group type: EXPERIMENTAL
Intervention: Alosetron 4 mg b.d.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo b.d.
Number of subjects: 22
Study: 10803997

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 70
Study: 7611868

Group type: EXPERIMENTAL
Intervention: Collagen type IV concentration measurement in peritoneal fluid
Number of subjects: 49
Study: 2292350

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg i.v.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 16
Study: 6786673

Group type: EXPERIMENTAL
Intervention: 0.25-0.5 microgram oral 1,25-dihydroxy vitamin D3
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 31072217

Group type: EXPERIMENTAL
Intervention: Evening aerobic exercise (30 min at 75% HRmax)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Evening resistance exercise (30 min at 75% of 10-repetition maximum)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 12
Study: 30219790

Group type: EXPERIMENTAL
Intervention: Thrombectomy within 0-6 hours
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Thrombectomy within 6-16 hours
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Thrombectomy within 16-24 hours
Number of subjects: 830
Study: 28049262

Group type: EXPERIMENTAL
Intervention: Low dose (110 mg BTPP) of black tea drink
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High dose (220 mg BTPP) of black tea drink
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo drink (0 mg BTPP)
Number of subjects: 24
Study: 25977992

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125% + sufentanil 0.75 μg/mL
Number of subjects: 181

Group type: COMPARATOR
Intervention: Ropivacaine 0.2% + sufentanil 0.75 μg/mL
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 181
Study: 25004353

Group type: EXPERIMENTAL
Intervention: Extremely obese (BMI > 45)
Number of subjects: 585
Study: 22796450

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy plus rectal insufflation of O(3)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Antithrombotic therapy only
Number of subjects: 53
Study: 20075532

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional opioid based analgesia
Number of subjects: 60
Study: 17353246

Group type: EXPERIMENTAL
Intervention: Fosfomycin (8 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15811655

Group type: EXPERIMENTAL
Intervention: 5 microg of AMA1
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 20 microg of AMA1
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 80 microg of AMA1
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: AMA1 (all doses)
Number of subjects: 29
Study: 12007591

Group type: EXPERIMENTAL
Intervention: Olanzapine (Olz)
Number of subjects: 1995

Group type: COMPARATOR
Intervention: Haloperidol (Hal)
Number of subjects: 1995
Study: 10463136

Group type: EXPERIMENTAL
Intervention: Propinox 20 mg
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Propinox 30 mg
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 7789347

Group type: EXPERIMENTAL
Intervention: Smokers smoking (SS) during light activity
Number of subjects: 39

Group type: COMPARATOR
Intervention: Smokers not smoking (SNS) during light activity
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nonsmokers (NS) during light activity
Number of subjects: 39

Group type: COMPARATOR
Intervention: All groups at rest
Number of subjects: 39
Study: 2407581

Group type: EXPERIMENTAL
Intervention: Highest quartile of fasting insulin distribution
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Fasting insulin
Number of subjects: 474

Group type: COMPARATOR
Intervention: BMI and centrality index
Number of subjects: 474
Study: 7041031

Group type: EXPERIMENTAL
Intervention: Vitamin A + Telecobalt irradiation
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Telecobalt irradiation
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vitamin A + Cytoxan
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Biologic therapy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Small cell carcinoma
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Squamous cell carcinoma
Number of subjects: 78
Study: 31834660

Group type: EXPERIMENTAL
Intervention: Immediate periodontal therapy (one‐stage scaling and root planning, amoxicillin 500 mg, metronidazole 400 mg, oral hygiene instructions)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Delayed periodontal therapy (control group)
Number of subjects: 88
Study: 30835526

Group type: EXPERIMENTAL
Intervention: Active Support training
Number of subjects: 75
Study: 29080862

Group type: EXPERIMENTAL
Intervention: Choline metabolite score (weighted sum of 5 metabolites: trimethylamine N-oxide, betaine, choline, phosphocholine, α-glycerophosphocholine)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Choline metabolite score
Number of subjects: 980

Group type: COMPARATOR
Intervention: Control group (Mediterranean diet)
Number of subjects: 980
Study: 25747518

Group type: EXPERIMENTAL
Intervention: HPV education and information sharing programs
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Culturally tailored HPV education programs
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Multilevel approach to address barriers
Number of subjects: 26
Study: 25067790

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention consisting of physical fitness training and counseling sessions
Number of subjects: 57
Study: 22803615

Group type: EXPERIMENTAL
Intervention: Ustekinumab (45 or 90 mg) with isoniazid (INH) prophylaxis
Number of subjects: 3177

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3177
Study: 19517674

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (100 microg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (25 microg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions (morphine and fentanyl)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 19087079

Group type: EXPERIMENTAL
Intervention: 10 mg oral nifedipine tablet
Number of subjects: 90

Group type: COMPARATOR
Intervention: 250 microgram bolus terbutaline subcutaneously
Number of subjects: 90
Study: 15870622

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12496548

Group type: EXPERIMENTAL
Intervention: Stoppa technique
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Laparoscopic extraperitoneal repair (TEPP)
Number of subjects: 39
Study: 9263935

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increasing employees' participation and control (organizational intervention)
Number of subjects: 0
Study: 8203837

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (SPX) 400 mg on day 1 and 200 mg on days 2 to 8
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (SPX)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3300178

Group type: EXPERIMENTAL
Intervention: Trimethoprim 300 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24